Search by Drug Name or NDC
NDC 72426-0818-03 Nexlizet 180; 10 mg/1; mg/1 Details
Nexlizet 180; 10 mg/1; mg/1
Nexlizet is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Esperion Therapeutics, Inc.. The primary component is BEMPEDOIC ACID; EZETIMIBE.
MedlinePlus Drug Summary
Bempedoic acid is used together with lifestyle changes (diet, weight-loss, exercise) and certain cholesterol-lowering medications (HMG-CoA reductase inhibitors [statins]) to further decrease low-density lipoprotein (LDL) cholesterol ('bad cholesterol') in the blood of adults with familial heterozygous hypercholesterolemia (HeFH; an inherited condition in which cholesterol cannot be removed from the body normally) or heart disease. Bempedoic acid is in a class of medications called adenosine triphosphate-citrate lyase (ACL) inhibitors. It works by blocking the production of cholesterol in the liver.
Related Packages: 72426-0818-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Bempedoic Acid
Ezetimibe is used together with lifestyle changes (diet, weight-loss, exercise) to reduce the amount of cholesterol (a fat-like substance) and other fatty substances in the blood. It may be used alone or in combination with an HMG-CoA reductase inhibitor (statin). Ezetimibe is in a class of medications called cholesterol-lowering medications. It works by preventing the absorption of cholesterol in the intestine. Buildup of cholesterol and fats along the walls of the blood vessels (a process known as atherosclerosis) decreases blood flow, which decreases the oxygen supply to the heart, brain, and other parts of the body. Lowering blood levels of cholesterol and fats may help reduce this buildup and may decrease your chances of developing heart conditions such as angina (chest pain), strokes, and heart attacks. Results of a clinical study that compared people who took ezetimibe and simvastatin with people who took simvastatin alone found that although the group of people taking ezetimibe and simvastatin had lower amounts of cholesterol in the blood, there was no difference between the two groups in the amount of cholesterol and fat buildup on the insides of the blood vessels in the neck. It is not currently understood why the additional lowering of cholesterol levels in the blood did not lead to a greater decrease in cholesterol and fat buildup along the walls of the blood vessels in people taking ezetimibe and simvastatin. Further studies are underway to compare treatment with ezetimibe and simvastatin to treatment with simvastatin alone to see if there is a difference in the risk of developing heart disease. Talk to your doctor if you have questions about the risks and benefits of treating increased amounts of cholesterol in your blood with ezetimibe and other medications. In addition to taking a cholesterol-lowering medication, making certain changes in your daily habits can also lower your blood cholesterol levels. You should eat a diet that is low in saturated fat and cholesterol (see SPECIAL DIETARY); exercise 30 minutes on most, if not all, days; and lose weight if you are overweight.
Related Packages: 72426-0818-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Ezetimibe
Product Information
| NDC | 72426-0818 |
|---|---|
| Product ID | 72426-818_eec27ac3-c444-4088-9fc0-d75e24913695 |
| Associated GPIs | 39991002200320 |
| GCN Sequence Number | 080790 |
| GCN Sequence Number Description | bempedoic acid/ezetimibe TABLET 180MG-10MG ORAL |
| HIC3 | M4W |
| HIC3 Description | ANTIHYPERLIPIDEMIC-ACLY AND CHOLES ABSORP INHIB |
| GCN | 47765 |
| HICL Sequence Number | 046386 |
| HICL Sequence Number Description | BEMPEDOIC ACID/EZETIMIBE |
| Brand/Generic | Brand |
| Proprietary Name | Nexlizet |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Bempedoic Acid and Ezetimibe |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 180; 10 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | BEMPEDOIC ACID; EZETIMIBE |
| Labeler Name | Esperion Therapeutics, Inc. |
| Pharmaceutical Class | Adenosine Triphosphate-Citrate Lyase Inhibitor [EPC], Adenosine Triphosphate-Citrate Lyase Inhibitors [MoA], Decreased Cholesterol Absorption [PE], Dietary Cholesterol Absorption Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA211617 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72426-0818-03 (72426081803)
| NDC Package Code | 72426-818-03 |
|---|---|
| Billing NDC | 72426081803 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72426-818-03) |
| Marketing Start Date | 2020-03-09 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 13.0425 |
| Pricing Unit | EA |
| Effective Date | 2024-01-01 |
| NDC Description | NEXLIZET 180-10 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |